PharmaTimes -
July/August 2016

It's not often that the pharmaceutical and medical community are in total agreement. Yet, at this moment in history, the consensus view is that the drugs emerging from the pharma pipeline over the coming years will utterly transform many diseases.

The sheer scale of innovation – standing on the shoulders of some of the greatest scientific discoveries of all time – is astounding. Many of these drugs are biologics and many of them very expensive. What's more, many of these very expensive drugs are being used in combination to deliver extraordinary effectiveness.

But who pays? After all, a drug is only effective if we can afford to pay for it. Healthcare systems were barely coping before the financial crisis of 2008 and many are in decline through lack of funds in this age of austerity. One solution to this global crisis touted by many are the biosimilars; highly similar versions of biopharmaceuticals that have lost exclusivity.

This year, we celebrate a decade of biosimilar use here in Europe, yet the market is very much in its infancy. There are still many unknowns and no one can answer that most pressing of questions – how much will biosimilars save health systems? In Same Difference, we explore that question and ask many more.

July 2016 - magazine highlights

Thumbnail image for Same difference

Same difference

With some of the world's biggest biologics teetering on the edge of the patent cliff, biosimilars are big business. Yet, with the market still in its infancy, it's not as easy as you might think to get these cheap biologics to the patients that need them

Thumbnail image for A shot in the arm

A shot in the arm

An ailing NHS needs an injection of innovation to survive. PharmaTimes speaks to the bright thinkers helping to transform the UK's health service

Thumbnail image for SmartViews: Staying power

SmartViews: Staying power

Building reputation is a long-term endeavour yet as pharma moves away from a traditional B2B model to embrace patients, it is becoming a crucial success factor

Thumbnail image for SmartViews: Never say never

SmartViews: Never say never

Pharmaceutical firms might reconsider any mergers or acquisitions that were initially ruled out as too challenging

Thumbnail image for SmartViews: One small step

SmartViews: One small step

With moves towards greater transparency gaining momentum, pharma must do all it can to ensure patient safety

Thumbnail image for SmartPeople: Mission possible

SmartPeople: Mission possible

An ailing NHS needs an injection of innovation to survive. PharmaTimes speaks to the bright thinkers helping to transform the UK's health service

Thumbnail image for SmartPeople: Talking about a revolution

SmartPeople: Talking about a revolution

We live in exciting times of cutting-edge science, truly innovative new medicines and positive changes towards patient-centricity, says Janssen's Jane Griffiths

Thumbnail image for Patient Files: Melanoma

Patient Files: Melanoma

Since being diagnosed with melanoma, Imogen Cheese has dedicated her life to bringing patients together

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download